Literature DB >> 30950007

The role of artificial nutrition in gynecological cancer therapy.

Magdalena Szewczuk1, Emilia Gasiorowska2, Konrad Matysiak3, Ewa Nowak-Markwitz2.   

Abstract

Cancer patients are at risk of developing malnutrition from underlying disease as well as from cancer treatment. Moreover, weight loss is considered as a predictive factor for disease progression and shorter survival time. As many as 10-20% of patients with cancer die from the results of malnutrition, instead of from the cancer itself. In the case of cancer-related malnutrition, it is necessary to quickly implement individualized nutritional support depending on the type and stage of the disease, metabolic changes, the patient's condition, expected survival and the function of the gastrointestinal tract. Artificial nutrition reduces the side effects of chemotherapy and improves immunity. Perioperatively it reduces the risk of infection, facilitates wound healing and shortens the length of hospitalization, thereby reducing the costs of the treat- ment. Initially, a malnourished patient, without gastrointestinal dysfunction, qualifies for nutritional counseling. When the energy needs cannot be met by normal feeding, nutritional supplements, taken orally, are recommended. The next step is to feed the patient by nasogastric tube or percutaneous endoscopic gastrostomy. Parenteral nutrition, which results in more side effects, is only started when enteral nutrition is insufficient to ensure adequate nutritional status or in cases of gastrointestinal tract obstruction. The benefit of parenteral nutrition is that it especially provides for those patients with gynaecological cancer who have radiation-induced intestinal damage and post-surgical complications such as short bowel syndrome. Palliative nutrition must to relieve hunger and thirst. Nutritional interventions should be individualized and focused on the changing nutrient needs of the patient and should be supported by physical activity. Regular assessment of the nutritional status of the patient should be an inherent element of the oncological treatment.

Entities:  

Keywords:  enteral nutrition; gynecological cancers; malnutrition; nutritional treatment; parenteral nutrition

Year:  2019        PMID: 30950007     DOI: 10.5603/GP.2019.0027

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  5 in total

Review 1.  Pre-treatment sarcopenic assessments as a prognostic factor for gynaecology cancer outcomes: systematic review and meta-analysis.

Authors:  E H Sutton; M Plyta; K Fragkos; S Di Caro
Journal:  Eur J Clin Nutr       Date:  2022-02-22       Impact factor: 4.016

2.  Milk and Egg Are Risk Factors for Adverse Effects of Capecitabine-Based Chemotherapy in Chinese Colorectal Cancer Patients.

Authors:  Jinrong Xu; Zeshuai Lin; Jiani Chen; Jian Zhang; Wanqing Li; Rui Zhang; Jin Xing; Zhihuan Ye; Xiaoping Liu; Qianmin Gao; Xintao Chen; Jingwen Zhai; Houshan Yao; Mingming Li; Hua Wei
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

3.  Application value of NRS2002 and PG-SGA in nutritional assessment for patients with cervical cancer surgery.

Authors:  Min Tian; Huaping Fu; Juan Du
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 4.  Nutrition in Gynecological Diseases: Current Perspectives.

Authors:  Michał Ciebiera; Sahar Esfandyari; Hiba Siblini; Lillian Prince; Hoda Elkafas; Cezary Wojtyła; Ayman Al-Hendy; Mohamed Ali
Journal:  Nutrients       Date:  2021-04-02       Impact factor: 5.717

5.  Prevalence of malnourishment and predictive factors associated with the nutritional status of gynecologic cancer patients undergoing chemotherapy: a cross-sectional analysis.

Authors:  Khemmanat Sanguanwongthong; Prapaporn Suprasert
Journal:  Obstet Gynecol Sci       Date:  2022-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.